Stock BOLD BOUNDLESS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Boundless Bio, Inc.

Equities

BOLD

US10170A1007

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-28 EDT 		5-day change 1st Jan Change
9.6 USD -15.12% Intraday chart for Boundless Bio, Inc. -12.65% 0.00%
04-22 Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target MT
04-22 Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
BU
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
BU
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
BU
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA -Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
AQ
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BOLD Stock
  4. News Boundless Bio, Inc.
  5. Press Releases